VANCOUVER, British Columbia & GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has filed its unaudited quarterly financial statements and management's discussion and analysis for the period ended Nov. 30, 2017. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.bioasis.us.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., President and Chief Executive Officer
About Bioasis
Bioasis Technologies, Inc. is a preclinical
biopharmaceutical company focused on the delivery of therapeutics across
the blood-brain barrier (BBB) and into the central nervous system for
the treatment of neurological diseases and disorders. The delivery of
therapeutics across the BBB represents the single greatest challenge in
treating neurological disorders. The company is developing and
commercializing the xB3 platform, Bioasis’ proprietary
blood-brain barrier delivery technology, to address unmet medical needs
in the treatment of central nervous system diseases and disorders. The
company maintains headquarters in Vancouver, Canada with offices in
Guilford, Conn., United States. Bioasis trades on the OTCQB under the
symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.”
For more information about the company please visit www.bioasis.ca
or www.bioasis.us.
Forward Looking Statements
Certain statements in this
press release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or forward-looking
information under applicable Canadian securities legislation that may
not be based on historical fact, including without limitation statements
containing the words “believe”, “may”, “plan”, “will”, “estimate”,
“continue”, “anticipate”, “intend”, “expect” and similar expressions.
Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments express or
implied by such forward-looking statements or information. Such factors
include, among others, our stage of development, lack of any product
revenues, additional capital requirements, risk associated with the
completion of clinical trials and obtaining regulatory approval to
market our products, the ability to protect our intellectual property,
dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could cause
such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties
that: products that we develop may not succeed in preclinical or
clinical trials, or future products in our targeted corporate
objectives; our future operating results are uncertain and likely to
fluctuate; we may not be able to raise additional capital; we may not be
successful in establishing additional corporate collaborations or
licensing arrangements; we may not be able to establish marketing and
the costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other
factors as described in detail in our filings with the Canadian
securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update
such forward- looking statements and information to reflect subsequent
events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
